PRAMEF27: A Potential Drug Target and Biomarker for PRAME Family Members

Target Name: PRAMEF27

NCBI ID: G101929983

PRAMEF27

Other Name(s): PRAME family member 9/15-like | PRA27_HUMAN | PRAME family member 27

PRAMEF27: A Potential Drug Target and Biomarker for PRAME Family Members

PRAMEF27, also known as PRAMEF27-like protein 27, is a member of the PRAME family, which includes several tumor suppressor genes that have been implicated in the development and progression of various diseases, including cancer. The PRAME family members have been identified based on their ability to induce cell death, either through apoptosis or necroptosis, in various cell types. PRAMEF27 is one of the latest additions to the PRAME family, and its potential as a drug target or biomarker has been generating a lot of interest in recent years.

The PRAME family is characterized by the presence of a specific domain in the protein that contains a pro-apoptotic effector, which can induce cell death either through apoptosis or necroptosis. This domain is known as the \"ASC\" (Apoptosis-Inducing Sequence) and is a common feature in the PRAME family members. The presence of this domain suggests that PRAMEF27 may have similar effects on cell behavior.

PRAMEF27 is a 27 kDa protein that is expressed in various tissues, including brain, spleen, and heart. It is highly conserved, with a calculated amino acid sequence of 244 amino acids. PRAMEF27 is similar to other PRAME family members in terms of its structure and function, but it has some unique features that set it apart. For instance, PRAMEF27 has a unique N-terminal region that contains a leucine residue, which is not found in other PRAME family members. Additionally, PRAMEF27 has a unique C-terminal region that contains a tryptophan residue, which is also not found in other PRAME family members.

PRIMEF27 has been shown to have various functions in various organisms, including its role in cell death and its involvement in the immune response. For example, PRAMEF27 has been shown to induce cell death in various cell types, including cancer cells, and to play a role in the regulation of cell proliferation. Additionally, PRAMEF27 has been shown to be involved in the immune response, where it has been shown to be regulated by NF-kappa signaling.

Given its unique structure and function, PRAMEF27 has generated a lot of interest as a potential drug target or biomarker. One of the main advantages of PRAMEF27 as a drug target is its ability to induce cell death, which can be used to target cells that are resistant to traditional chemotherapy and radiation therapy. Additionally, PRAMEF27's unique structure and function make it a promising biomarker for various diseases, including cancer.

In conclusion, PRAMEF27 is a promising drug target and biomarker for various diseases, including cancer. Its unique structure and function make it an attractive target for drug development, as it has the potential to induce cell death and serve as a reliable biomarker for various diseases. Further research is needed to fully understand the role of PRAMEF27 in the immune response and its potential as a drug target or biomarker.

Protein Name: PRAME Family Member 27

The "PRAMEF27 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRAMEF27 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets